Literature DB >> 17721387

No decrease in clindamycin susceptibility despite increased use of clindamycin for pediatric community-associated methicillin-resistant Staphylococcus aureus skin infections.

Jillian M Szczesiul1, Kenneth M Shermock, Umbreen Idrees Murtaza, George K Siberry.   

Abstract

A previous study at our institution revealed 98% of methicillin-resistant Staphylococcus aureus (MRSA) isolates were susceptible to clindamycin; however, beta-lactams were then the predominant empiric treatment. This follow-up chart review study examined subsequent staphylococcal skin and soft tissue infection treatment and susceptibility patterns over a 2-year period. Of 296 S. aureus skin and soft tissue infections, 73% were MRSA, of which 87% were community-associated-MRSA; MRSA infections peaked in warm summer months. Despite a significant increase in empiric clindamycin use, 97% of community-associated-MRSA isolates retained susceptibility to clindamycin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17721387     DOI: 10.1097/INF.0b013e318124aa5c

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  9 in total

1.  Differences in methicillin-resistant Staphylococcus aureus strains isolated from pediatric and adult patients from hospitals in a large county in California.

Authors:  Lyndsey O Hudson; Courtney R Murphy; Brian G Spratt; Mark C Enright; Leah Terpstra; Adrijana Gombosev; Paul Hannah; Lydia Mikhail; Richard Alexander; Douglas F Moore; Susan S Huang
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

Review 2.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

3.  Methicillin-resistant Staphylococcus aureus colonization and risk of subsequent infection in critically ill children: importance of preventing nosocomial methicillin-resistant Staphylococcus aureus transmission.

Authors:  Aaron M Milstone; Brian W Goldner; Tracy Ross; John W Shepard; Karen C Carroll; Trish M Perl
Journal:  Clin Infect Dis       Date:  2011-08-29       Impact factor: 9.079

4.  Human-associated methicillin-resistant Staphylococcus aureus from a subtropical recreational marine beach.

Authors:  Lisa R W Plano; Tomoyuki Shibata; Anna C Garza; Jonathan Kish; Jay M Fleisher; Christopher D Sinigalliano; Maribeth L Gidley; Kelly Withum; Samir M Elmir; Suzanne Hower; Charlene R Jackson; John B Barrett; Timothy Cleary; Maureen Davidson; Johnnie Davis; Sampa Mukherjee; Lora E Fleming; Helena M Solo-Gabriele
Journal:  Microb Ecol       Date:  2013-04-04       Impact factor: 4.552

5.  Seasonality of MRSA infections.

Authors:  Leonard A Mermel; Jason T Machan; Stephen Parenteau
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

6.  Community-associated methicillin-resistant Staphylococcus aureus strains in pediatric intensive care unit.

Authors:  Aaron M Milstone; Karen C Carroll; Tracy Ross; K Alexander Shangraw; Trish M Perl
Journal:  Emerg Infect Dis       Date:  2010-04       Impact factor: 6.883

7.  Current role of community-acquired methicillin-resistant Staphylococcus aureus among children with skin and soft tissue infections.

Authors:  Carlos G Teran; Sunitha Sura; Tarek Mohamed; Thant Lin; Marsha Meadows; Donkor Cynthia; Sze H Wong
Journal:  Pediatr Rep       Date:  2012-01-17

8.  A population based study of seasonality of skin and soft tissue infections: implications for the spread of CA-MRSA.

Authors:  Xiaoxia Wang; Sherry Towers; Sarada Panchanathan; Gerardo Chowell
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

9.  Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis.

Authors:  Vanja M Dukic; Diane S Lauderdale; Jocelyn Wilder; Robert S Daum; Michael Z David
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.